Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7748/paed.15.7.34.s27 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of intramuscular treatment with different iron dextran dosages and non-inferiority study to gleptoferron.
Acta Vet Scand
January 2025
Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Grønnegårdsvej 2, 1870, Frederiksberg C, Denmark.
Background: Prevention of iron deficiency in suckling piglets by intramuscular injection of a standardized amount of iron dextran or gleptoferron in the first days of life can lead to over- or underdosage with respective health risks. Currently, combined iron products containing an active substance against coccidia are also used on farms. When using a combination product targeting two diseases, an adjustment of the necessary amount of iron to prevent anaemia in the frame of a farm-specific treatment protocol is not possible.
View Article and Find Full Text PDFReallocating Time Between 24-h Movement Behaviors for Obesity Management Across the Lifespan: A Pooled Data Meta-Analysis of More Than 9800 Participants from Seven Countries.
Sports Med
December 2024
Australian Catholic University, North Sydney, NSW, Australia.
Article Synopsis
- The study investigates how reallocating time among physical activity, sedentary behavior, and sleep affects obesity indicators like BMI and waist circumference across various age groups.
- Researchers analyzed data from 9,818 participants using isotemporal substitution models to understand the implications of these behavior changes.
- Results indicated that even small shifts of 10-30 minutes can significantly impact obesity, with reallocating moderate-to-vigorous physical activity (MVPA) to lighter activities or sedentary behavior having particularly detrimental effects.
Upgrade constructed wetlands wastewater quality by solar-driven photochemical quaternary treatments in raceway pond reactor at pilot plant scale.
Sci Total Environ
December 2024
CIESOL, Centro Mixto UAL-CIEMAT, E-04120 Almería, Spain; Department of Chemistry and Physics, University of Almería, Ctra. de Sacramento s/n, 04120 Almería, Spain.
This study explores the potential application of solar photochemical processes (SPPs) for simultaneous disinfection and decontamination of urban wastewater (UWW) when combined with constructed wetlands (CWs). Two SPPs based on the addition of low concentrations of hydrogen peroxide and peroxymonosulfate (PMS) were evaluated. SPPs were carried out at pilot plant scale using low-cost solar open photoreactors (Raceway Pond Reactor (RPR)) under natural sunlight.
View Article and Find Full Text PDFClinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.
Diabetes Ther
December 2024
Bayer AG, Berlin, Germany.
Introduction: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).
Methods: This was a multinational, multi-cohort study of patients with T2D in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics Data Mart Database (CDM) (US).
Interindividual variability in CYP3A-mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia.
Clin Transl Sci
December 2024
Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Venetoclax is a first-in-class orally administered B-cell lymphoma-2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its major metabolite M27, via M5, and M2, M3, and M4 via oxidation. Although venetoclax is a breakthrough in CLL treatment, managing drug safety and toxicity remains a clinical challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!